Tag: Mabthera

MabThera, the European trade name for the drug rituximab, is a powerful chimeric monoclonal antibody that targets the CD20 protein on the surface of B-cells. In 1998, it received European approval and has since become a standard treatment for several specific B-cell malignancies and autoimmune disorders.

Ristova and rituximab are not the same, with rituximab being the active ingredient within the brand-name medication Ristova. This is a common relationship in the pharmaceutical industry, where a single active compound is marketed under different brand names by various manufacturers around the world.